Abstract
Background and Objectives
Imeglimin (IMEG) is the first in a novel class of oral glucose-lowering agents with a unique mechanism of action targeting mitochondrial bioenergetics. We assessed whether repeated co-administration of IMEG and either metformin (MET) or sitagliptin (SITA) would influence the pharmacokinetics of either MET or SITA in healthy Caucasian men.
Methods
Healthy Caucasian men received either MET 850 mg twice daily with placebo (n = 16) or SITA 100 mg once daily with placebo (n = 16) on days 1–6, followed by MET 850 mg twice daily with IMEG 1500 mg twice daily or SITA 100 mg once daily with IMEG 1500 mg twice daily on days 7–12. Pharmacokinetic parameters were determined from blood and urine; levels of all compounds were evaluated using liquid chromatography with tandem mass spectrometry.
Results
Systemic exposure (AUC0–τ area under the plasma concentration-time curve over a dosing interval and maximum concentration) to MET was 14% and 10% lower, respectively, when administered with IMEG. Approximately 40% of MET was excreted unchanged in urine, decreasing to 34% when given with IMEG. The 90% confidence intervals for AUC0–τ and maximum concentration indicated no effect of co-administration on systemic exposure to MET. Mean AUC0–τ and maximum concentration of SITA were similar with or without IMEG. Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively. Systemic exposure to IMEG was similar to previous phase I studies.
Conclusions
Co-administration of IMEG with MET or SITA did not result in clinically relevant changes in systemic exposure to MET or SITA, although minor reductions in exposure (AUC0–τ and maximum concentration) and renal elimination were noted when MET was given with IMEG vs placebo.
Clinical Trial Registration
EudraCT2009-014520-40 (MET-IMEG DDI) and EudraCT2010-022926-34 (SITA-IMEG DDI)
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Lavernia F, Adkins SE, Shubrook JH. Use of oral combination therapy for type 2 diabetes in primary care: meeting individualized patient goals. Postgrad Med. 2015;127(8):808–17.
Pirags V, Lebovitz H, Fouqueray P. Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab. 2012;14(9):852–8.
Fouqueray P, Pirags V, Inzucchi SE, Bailey CJ, Schernthaner G, Diamant M, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care. 2013;36(3):565–8.
Fouqueray P, Pirags V, Diamant M, Schernthaner G, Lebovitz HE, Inzucchi SE, et al. The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. Diabetes Care. 2014;37(7):1924–30.
Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, et al. Imeglimin normalizes glucose tolerance and insulin senitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes. 2015;64(6):2254–64.
Pacini G, Mari A, Fouqueray P, Bolze S, Roden M. Imeglimin increases glucose-dependent insulin secretion and improves beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17(6):541–5.
Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, et al. Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell Death Discov. 2016;2:15072.
EMA. Guideline on bioanalytical method validation, EMEA/CHMP/EWP/192217/2009, Rev. 1 Corr. 2, 21 July 2011.
US FDA. Guidance for industry, bioanalytical method validation, US Department of Health and Human Sciences/FDA/CDER/CVM, 2013.
Gabrielsson J, Weiner D. Non-compartmental analysis. Methods Mol Biol. 2012;929:377–89.
Data on file, Poxel.
Glucophage 850 mg: summary of product characteristics. 2009.
Herman GA, Bergman A, Yi B, Kipnes M. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22(10):1939–47.
Herman GA, Stevens C, Van Dyck K, et al. PKs and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther. 2005;78:675–88.
Bergman AJ, Stevens C, Zhou Y, et al. PK and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.
Chu XY, Bleasby K, Yabut J, Cai X, Chan GH, Hafey MJ, et al. Transport of the dipeptidyl peptidase-4 inhibitor sitagliptin by human organic anion transporter 3, organic anion transporting polypeptide 4C1, and multidrug resistance P-glycoprotein. J Pharmacol Exp Ther. 2007;321(2):673–83.
Author information
Authors and Affiliations
Contributions
PF and SB designed the studies. All authors were involved in the preparation of the manuscript, provided input, and reviewed the final draft for publication.
Corresponding author
Ethics declarations
Funding
This study was funded by Poxel SA.
Conflict of interest
Pascale Fouqueray, Sandrine Perrimond-Dauchy, and Sébastien Bolze are Poxel employees and may own stocks or stock options.
Rights and permissions
About this article
Cite this article
Fouqueray, P., Perrimond-Dauchy, S. & Bolze, S. Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects. Clin Pharmacokinet 59, 1261–1271 (2020). https://doi.org/10.1007/s40262-020-00886-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40262-020-00886-y